Cancel
Serinus Biosciences
See Linkedin
Serinus Biosciences Employees
7 people indexed:
-
kk4k@v3jj7ll.yxj Sign up to see email
-
3xt4fxz@t31txwf.h53 Sign up to see email
-
xqthzmv39.1k4j9k@0z8ylyz.z53 Sign up to see email
-
7x9@phxap3m.adv Sign up to see email
-
6qg@wy3l1fl.qfq Sign up to see email
-
g35ppd@hqg0ady.30w Sign up to see email
-
4mp0g@101cwc2.h27 Sign up to see email
Serinus Biosciences Company Information
Serinus Biosciences, formerly known as Serinus, is a healthcare company located in New York, NY, specializing in the therapeutics sub-industry. The company, founded by MIT PhDs, is at the forefront of creating innovative combination therapies aimed at overcoming treatment resistance in cancer. Serinus Biosciences harnesses a sophisticated AI engine designed for biological inference, which helps in understanding how cancer cells develop resistance to treatments. This AI platform is enriched with decades of system biology knowledge and is capable of identifying molecules that can block these resistance pathways. The designed therapies are intended to be safer, more effective, and delivered to patients more swiftly. The company is supported by a notable scientific advisory board comprising leading academics from institutions like the Broad Institute, Dana-Farber Cancer Institute, and UCSD. As a participant in the Y-Combinator S22 batch, Serinus Biosciences is backed by Y Combinator and other top investors, aiming to revolutionize precision medicine in oncology. Currently, the team consists of six members and operates in various regions including the United States, America/Canada, and offers remote and partly remote services.
Report inaccurate information
Report inaccurate information